Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

INTERVENTIONALInicio: 8 de oct de 2025ID: NCT07190248

ReclutandoFase 3ClinicalTrials.gov

Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and/or Df

INTERVENTIONALInicio: 2 de abr de 2025ID: NCT07348302

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants With Inadequately Controlled Moderate-to-Severe Asthma

INTERVENTIONALInicio: 20 de may de 2025ID: NCT06977581

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

INTERVENTIONALInicio: 20 de sept de 2018ID: NCT03683251

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

INTERVENTIONALInicio: 11 de oct de 2023ID: NCT06012240

ReclutandoFase 4ClinicalTrials.gov

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment

INTERVENTIONALInicio: 30 de ago de 2022ID: NCT04877522

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

INTERVENTIONALInicio: 24 de oct de 2025ID: NCT06899126

ReclutandoClinicalTrials.gov

Trauma-informed Obstetric Care for Perinatal Health in Women With Histories of Childhood Abuse: a Pilot Randomized Clinical Trial

INTERVENTIONALInicio: 23 de may de 2025ID: NCT07195058

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

INTERVENTIONALInicio: 25 de jul de 2025ID: NCT07037433

ReclutandoFase 3ClinicalTrials.gov

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

INTERVENTIONALInicio: 22 de nov de 2024ID: NCT06647498

ReclutandoFase 3ClinicalTrials.gov

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

INTERVENTIONALInicio: 31 de mar de 2023ID: NCT05774951

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)

INTERVENTIONALInicio: 9 de jun de 2025ID: NCT06872892

ReclutandoFase 3ClinicalTrials.gov

An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

INTERVENTIONALInicio: 12 de dic de 2024ID: NCT06716606

ReclutandoFase 3ClinicalTrials.gov

Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

INTERVENTIONALInicio: 23 de sept de 2022ID: NCT05327114

ReclutandoClinicalTrials.gov

Music to Prevent Delirium: A Prospective, Randomized, Controlled, Three-Arm Parallel-Group Clinical Trial in an Argentine Intensive Care Unit

INTERVENTIONALInicio: 2 de feb de 2026ID: NCT07369258

ReclutandoClinicalTrials.gov

Comparative Analysis of Diet and Cardiometabolic Health in Individuals Following Vegan, Vegetarian, and Omnivorous Diets in the City of Rosario

OBSERVATIONALInicio: 1 de dic de 2025ID: NCT07247487

ReclutandoClinicalTrials.gov

Impact of Active Learning on Beliefs, Attitudes, Perceived Skills, and Application of Evidence-Based Practice in Undergraduate Physiotherapy Students

INTERVENTIONALInicio: 31 de mar de 2025ID: NCT06945367

ReclutandoClinicalTrials.gov

NeuroVascular Product Surveillance Registry (PSR) Platform

OBSERVATIONALInicio: 1 de dic de 2016ID: NCT02988128

ReclutandoFase 2ClinicalTrials.gov

A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants With Moderate or Severe Asthma

INTERVENTIONALInicio: 24 de jul de 2025ID: NCT07120503

ReclutandoFase 3ClinicalTrials.gov

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

INTERVENTIONALInicio: 10 de mar de 2025ID: NCT06671496